Literature DB >> 15767358

Centralized blood processing for the selenium and vitamin E cancer prevention trial: effects of delayed processing on carotenoids, tocopherols, insulin-like growth factor-I, insulin-like growth factor binding protein 3, steroid hormones, and lymphocyte viability.

Alan R Kristal1, Irena B King, Demetrius Albanes, Michael N Pollak, Frank Z Stanzyk, Regina M Santella, Ashraful Hoque.   

Abstract

This experiment examined the effects of delays in separation and freezing of whole blood components on analytes of interest in studies of prostate cancer prevention, in order to evaluate the feasibility of centralized processing of blood for the multisite Selenium and Vitamin E Cancer Prevention Trial. Blood from 40 healthy men was subjected to four treatment protocols, allowing the contrast of immediate processing to delays of 32, 72, and 144 hours. At 32 hours, simulating refrigerated storage and overnight shipping, there was a 2.9% decrease (95% confidence interval, 0.7-5.1) in insulin-like growth factor-I (IGF-I) but no significant change in carotenoids, tocopherols, testosterone, 3alpha-androstanediol glucuronide (AAG), sex hormone-binding globulin (SHBG) or insulin-like growth factor binding protein 3 (IGFBP3). A 144-hour processing delay, simulating weekend blood collection or shipping delay, resulted in significant changes in gamma-tocopherol (-1.5%), IGF-I (-5.7%), IGFBP3 (-2.9%), SHBG (-4.0%), testosterone (+4.7%), and AAG (+5.5%). The rank-order and intraclass correlations between analytes from blood processed immediately and those subjected to delayed processing were 0.96 or higher for carotenoids, tocopherols, AAG, and SHBG, and between 0.87 and 0.95 for IGF-I, IGFBP3, and testosterone. A 32-hour delay decreased lymphocyte viability from 82.5% to 75.0% (P = 0.45), but a 72-hour delay decreased viability to 36.8% (P < 0.001). Overnight shipping and centralized processing is an acceptable approach to blood collection in large multisite trials examining the cancer-related measures proposed in the Selenium and Vitamin E Cancer Prevention Trial. Longer processing delays, however, have small but statistically significant effects on many analytes and substantially decrease lymphocyte viability.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15767358     DOI: 10.1158/1055-9965.EPI-04-0596

Source DB:  PubMed          Journal:  Cancer Epidemiol Biomarkers Prev        ISSN: 1055-9965            Impact factor:   4.254


  9 in total

1.  Serum phospholipid fatty acids and prostate cancer risk: results from the prostate cancer prevention trial.

Authors:  Theodore M Brasky; Cathee Till; Emily White; Marian L Neuhouser; Xiaoling Song; Phyllis Goodman; Ian M Thompson; Irena B King; Demetrius Albanes; Alan R Kristal
Journal:  Am J Epidemiol       Date:  2011-04-24       Impact factor: 4.897

2.  Finasteride modifies the relation between serum C-peptide and prostate cancer risk: results from the Prostate Cancer Prevention Trial.

Authors:  Marian L Neuhouser; Cathee Till; Alan Kristal; Phyllis Goodman; Ashraful Hoque; Elizabeth A Platz; Ann W Hsing; Demetrius Albanes; Howard L Parnes; Michael Pollak
Journal:  Cancer Prev Res (Phila)       Date:  2010-02-23

3.  Insulin-like growth factors and insulin-like growth factor-binding proteins and prostate cancer risk: results from the prostate cancer prevention trial.

Authors:  Marian L Neuhouser; Elizabeth A Platz; Cathee Till; Catherine M Tangen; Phyllis J Goodman; Alan Kristal; Howard L Parnes; Yuzhen Tao; William D Figg; M Scott Lucia; Ashraful Hoque; Ann W Hsing; Ian M Thompson; Michael Pollak
Journal:  Cancer Prev Res (Phila)       Date:  2013-01-11

4.  Effect of long-term storage on hormone measurements in samples from pregnant women: the experience of the Finnish Maternity Cohort.

Authors:  Katsiaryna Holl; Eva Lundin; Marjo Kaasila; Kjell Grankvist; Yelena Afanasyeva; Göran Hallmans; Matti Lehtinen; Eero Pukkala; Helja-Marja Surcel; Paolo Toniolo; Anne Zeleniuch-Jacquotte; Pentti Koskela; Annekatrin Lukanova
Journal:  Acta Oncol       Date:  2007-09-24       Impact factor: 4.089

5.  Insulin-like growth factor-I, insulin-like growth factor binding protein-3 and risk of benign prostate hyperplasia in the prostate cancer prevention trial.

Authors:  Marian L Neuhouser; Jeannette Schenk; Yoon Ju Song; Catherine M Tangen; Phyllis J Goodman; Michael Pollak; David F Penson; Ian M Thompson; Alan R Kristal
Journal:  Prostate       Date:  2008-09-15       Impact factor: 4.104

Review 6.  The current status of IGF-I assays--a 2009 update.

Authors:  Jan Frystyk; Pamela Freda; David R Clemmons
Journal:  Growth Horm IGF Res       Date:  2009-10-08       Impact factor: 2.372

7.  Comparison of hematologic measurements between local and central laboratories: data from the BABY HUG trial.

Authors:  Ram Kalpatthi; Bruce Thompson; Ming Lu; Winfred C Wang; Niren Patel; Abdullah Kutlar; Thomas Howard; Lori Luchtman-Jones; Scott T Miller
Journal:  Clin Biochem       Date:  2012-10-31       Impact factor: 3.281

8.  Plasma phospholipid fatty acids and prostate cancer risk in the SELECT trial.

Authors:  Theodore M Brasky; Amy K Darke; Xiaoling Song; Catherine M Tangen; Phyllis J Goodman; Ian M Thompson; Frank L Meyskens; Gary E Goodman; Lori M Minasian; Howard L Parnes; Eric A Klein; Alan R Kristal
Journal:  J Natl Cancer Inst       Date:  2013-07-10       Impact factor: 13.506

9.  Extraction of DNA from serum for high-throughput genotyping: findings from pilot studies within the Prostate Cancer Prevention Trial.

Authors:  Ashraful Hoque; Phyllis Goodman; Christine B Ambrosone; William D Figg; Douglas K Price; William Kopp; Xifeng Wu; Jeffrey Conroy; Teresa A Lehman; Regina M Santella
Journal:  Urology       Date:  2008-02-11       Impact factor: 2.649

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.